Navigation Links
Patient's Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation
Date:6/18/2008

Case is first to show safety and effectiveness of using cloned cells alone

to kill tumors

SEATTLE, June 18 /PRNewswire/ -- Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.

Yee and colleagues removed CD4+ T cells, a type of white blood cell, from a 52-year-old man whose Stage 4 melanoma had spread to a groin lymph node and to a lung. T cells specific to targeting the melanoma were then expanded vastly in the laboratory using modifications to existing methods. The lab-grown cells were then infused into the patient with no additional pre- or post-conditioning therapies, such as growth-factor or cytokine treatment. Two months later, PET and CT scans revealed no tumors. The patient remained disease free two years later, when he was last checked.

"We were surprised by the anti-tumor effect of these CD4 T cells and its duration of response," Yee said. "For this patient we were successful, but we would need to confirm the effectiveness of therapy in a larger study."

Yee cautioned that these results, presented in the journal's "Brief Report" section, represent only one patient with a specific type of immune system whose tumor cells expressed a specific antigen. More studies are needed to confirm the effectiveness of the experimental T cell therapy. If proven successful in more patients, Yee predicted this therapy could be used for the 25 percent of all late-stage melanoma patients who have the same immune-system type and tumor antigen.

Using a patient's own immune system to combat cancer, called immunotherapy, is a growing area of research that aims to develop
'/>"/>

SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... new analysis of Centers for Medicare and Medicaid Services, ... 81 percent of seniors chose lower-cost preferred pharmacy plans ... pharmacies. The findings were released by Drug Channels ... foundation of Medicare Part D," said Pharmaceutical Care Management ...
(Date:1/23/2015)... NEW YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer ... the board of directors of Advaxis, Inc. ("Advaxis" or ... the board has breached its fiduciary duties to shareholders. ... published on an investing website reporting that Advaxis had ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Oct. 7 DiFUSION Technologies is a medical ... of its proprietary CleanFUZE™ antimicrobial technology for orthopedic ... Interbody products for spinal surgery. "Post-operative ... the further proliferation of drug resistant bacteria, preventing ...
... Community Pharmacists Association (NCPA) has announced its current ... and Trade Exposition scheduled for October 23-27, 2010 ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20100106/DC33253LOGO ) (Logo:   ... Exposition is the most powerful and productive trade ...
Cached Medicine Technology:DiFUSION Technologies Completes Successful Antimicrobial Implant Animal Trial 2DiFUSION Technologies Completes Successful Antimicrobial Implant Animal Trial 3NCPA Announces Exhibit Hall Activities for 2010 NCPA Annual Convention and Trade Exposition 2
(Date:1/23/2015)... Hastings and Hastings, a law firm in Arizona that focuses ... representation client review requests for slip and fall accidents in ... the number of slip and fall related accidents that happen ... that said, a large number of injury victims are requesting ... Hastings and Hastings is a personal injury firm in Arizona ...
(Date:1/22/2015)... 23, 2015 LunaDress, with its top dressmaking ... industry. Now, the business is showing its latest designs of ... , According to the company’s CEO, all the fresh new ... with big discounts, up to 80% off. All the clothes ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... treatment plan used to prevent potentially dangerous blood clots ... immobilized by acute medical illness, doctors have found in ... or older, and patients strictly confined to 24-hour bed ... thinner significantly reduced the chances of blood clots while ...
... Gardner HealthDay Reporter , TUESDAY, July 6 (HealthDay ... blood pressure levels in type 2 diabetics who also have ... and coronary artery disease did not have fewer strokes or ... their blood pressure was maintained under 130 mm Hg, compared ...
... in French . Montreal, July 6, ... Research in Immunology and Cancer (IRIC) of the University of ... (hematopoietic) stem cells. The study led by IRIC Chief Executive ... control the production of hematopoietic stem cells. Published in the ...
... than one species of bacteria could be more persistent ... the other, encouraging it to bolster its defenses. ... curing these infections. Researchers from Wake Forest University ... mBio , the online open-access journal of the American ...
... ... expansion into Brooklyn, New York through a merger with Otolaryngology Associates. , ... Tarrytown, NY (Vocus) July 6, 2010 -- ... into Brooklyn, New York through a merger with Otolaryngology Associates. This will result in a ...
... Los Angeles and childhood cancer patients will together take part in ... their hands in fingerpaint and apply colorful handprints to a white ... handprints from all over the country, is the symbol of Hyundai ... cure rate means that in the general population of young adults, ...
Cached Medicine News:Health News:Extended use of anti-clotting drug helps some bedridden patients 2Health News:Extended use of anti-clotting drug helps some bedridden patients 3Health News:Tight Blood Pressure Control Doesn't Help All Diabetics: Study 2Health News:Researchers identify factors behind blood-making stem cells 2Health News:Bacterial communication encourages chronic, resistant ear infections 2Health News:ENT and Allergy Associates Adds Two Offices in Brooklyn, NY -- Practice Grows to 110 Physicians, 2Health News:ENT and Allergy Associates Adds Two Offices in Brooklyn, NY -- Practice Grows to 110 Physicians, 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: